Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP5 | P45974 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CD69 | Q07108 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12503737 | 0.83 | CYP19A1 (0.37) | CYP19A1FOLH1NOTUM | |
| SCHEMBL9768670 | 0.83 | CYP19A1 (0.37) | CYP19A1FOLH1NOTUM | |
| SCHEMBL16964247 | 0.79 | CYP19A1 (0.38) | CYP19A1FOLH1PPARG | |
| SCHEMBL10360818 | 0.79 | CYP19A1 (0.34) | CYP19A1ALDH1A1KDM4E | |
| SCHEMBL4057468 | 0.76 | NPSR1 (0.36) | CYP19A1ALDH1A1KDM4E | |
| SCHEMBL20514206 | 0.75 | CYP19A1 (0.41) | CYP19A1FOLH1PPARGCYP1A1 | |
| SCHEMBL15532588 | 0.75 | PPARG (0.40) | CYP19A1ALDH1A1FOLH1KDM4EPPARG | |
| SCHEMBL3533905 | 0.73 | — | — | |
| SCHEMBL1101978 | 0.72 | — | — | |
| SCHEMBL20816252 | 0.72 | GABRP (0.42) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847183-B1 | PROCESS FOR THE PREPARATION OF TRIAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | claimed |
| WO-2014015137-A2 | COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | ANGION BIOMEDICA CORP. (US) | 2014-01-23 | — | — | WO | claimed |
| EP-1893582-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006127503-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2006-11-30 | — | — | WO | claimed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3645533-A1 | TDO2 AND IDO1 INHIBITORS | Genentech, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019005559-A1 | TDO2 AND IDO1 INHIBITORS | GENENTECH, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-2847183-B1 | PROCESS FOR THE PREPARATION OF TRIAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| EP-2900665-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2014015137-A2 | COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | ANGION BIOMEDICA CORP. (US) | 2014-01-23 | — | — | WO | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0158448-B1 | AZOLYL PROPANOLS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | CYP19A1 456/4885ALDH1A1 822/4885FOLH1 2784/4885 |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | CYP19A1 999/4885ALDH1A1 2513/4885FOLH1 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.